Ortner Hadžiabdić, Maja

Link to this page

Authority KeyName Variants
faa3d3ed-568e-4f7c-b003-e2dc10c45440
  • Ortner Hadžiabdić, Maja (4)
  • Ortner-Hadžiabdić, Maja (1)
Projects
Charles University project, grant number: SVV 260 551 CharlesUniversity project, Research program Cooperatio, research unit KSKF-I Ageing, Polypharmacy and Changes inthe Therapeutic value of Drugs in the AgeD (Chair: Assoc. Prof. Daniela Fialova); Ministry of Education, Youthand Sports of the Czech Republic, Czech Operational Programme Research, Development and Education, STARTProgramme, grant number: CZ.02.2.69/0.0/0.0/19_073/0016935;
Cooperatio research program of the Faculty of Pharmacy, Charles University (Research Unit: “Ageing, Polypharmacotherapy and Changes in Therapeutic Value of Drugs in the Aged’’, KSKF-I. EuroAgeism project, grant number 764632.
European Union’s Horizon 2020 research andinnovation programme I-CARE4OLD project, grant number 965341 Innovation programme under the Marie Skłodowska‑Curie grant agreement No. 764632 (EuroAgeism H2020 ESR7 project)
Ministry ofEducation, Youth and Sports of the Czech Republic, Czech Operational Programme Research, Development andEducation, Pre-application research into innovative medicines and medical technologies (InoMed) project, grantnumber CZ.02.1.01/0.0/0.0/18_069/0010046; NETPHARM project CZ.02.01.01/00/22_008/0004607
Project ID: CZ.02.01.01/00/22_008/0004607) START/MED/093 EN.02.2.69/0.0/0.0/19_073/0016935
SVV 260 551 Grant The EuroAgeism H2020 ESR7 project
The EuroAgeism H2020 project The EuroAgeism H2020 project (ESR7 project)
The European Horizon 2020 I-CARE4OLD Grant No 965341 The European Union (EU) funded project InoMed, reg. No: CZ.02.1.01/0.0/0.0/18_069/0010 046 (2019–2022)
The European Union research and innovation program The European Union’s Horizon 2020
The European Union’s Horizon 2020 research and innovation programme under grant agreement No 965341 The grant agreement of the Marie Skłodowska‑Curie Foundation number MSCF‑ITN‑764632
The Grant Agreement of the Marie Skłodowska-Curie Founda- tion Number MSCF-ITN-764632 The Grants: InoMed, Reg. No CZ.02.1.01/0.0/0.0/18_069/0010046
The I‑CARE4 OLD Horizon 2020 project. The project START / MED / 093 EN.02.2.69 / 0.0 / 0.0 / 19_073 / 0016935 and SVV program 260 665, and the project NETPHARM (New Technologies for Translational Research in Pharmaceutical Sciences
The research group “Aging, polypharmacotherapy and changes in therapeutic value of drugs in the aged” (chair: Assoc. Prof. Daniela Fialova, PharmD., Ph.D.) The scientific program Cooperatio KSKF1 of the Faculty of Pharmacy, Charles Uni‑ versity in Hradec Kralove

Author's Bibliography

Clinical decision-making in benzodiazepine deprescribing by healthcare providers vs. AI-assisted approach

Bužančić, Iva; Belec, Dora; Držaić, Margita; Kummer, Ingrid; Brkić, Jovana; Fialová, Daniela; Ortner Hadžiabdić, Maja

(John Wiley and Sons Inc, 2024)

TY  - JOUR
AU  - Bužančić, Iva
AU  - Belec, Dora
AU  - Držaić, Margita
AU  - Kummer, Ingrid
AU  - Brkić, Jovana
AU  - Fialová, Daniela
AU  - Ortner Hadžiabdić, Maja
PY  - 2024
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5344
AB  - Aims: The aim of this study was to compare the clinical decision-making for benzodiazepine deprescribing between a healthcare provider (HCP) and an artificial intelligence (AI) chatbot GPT4 (ChatGPT-4). Methods: We analysed real-world data from a Croatian cohort of community-dwelling benzodiazepine patients (n = 154) within the EuroAgeism H2020 ESR 7 project. HCPs evaluated the data using pre-established deprescribing criteria to assess benzodiazepine discontinuation potential. The research team devised and tested AI prompts to ensure consistency with HCP judgements. An independent researcher employed ChatGPT-4 with predetermined prompts to simulate clinical decisions for each patient case. Data derived from human-HCP and ChatGPT-4 decisions were compared for agreement rates and Cohen's kappa. 
Results : Both HPC and ChatGPT identified patients for benzodiazepine deprescribing (96.1% and 89.6%, respectively), showing an agreement rate of 95% (κ=.200,P=.012). Agreement on four deprescribing criteria ranged from 74.7% to 91.3%(lack of indicationκ=.352,P< .001; prolonged useκ=.088,P=.280; safety concernsκ=.123,P=.006; incorrect dosageκ=.264,P=.001). Important limitationsof GPT-4 responses were identified, including 22.1% ambiguous outputs, genericanswers and inaccuracies, posing inappropriate decision-making risks.Conclusions : While AI-HCP agreement is substantial, sole AI reliance poses a risk forunsuitable clinical decision-making. This study's findings reveal both strengths andareas for enhancement of ChatGPT-4 in the deprescribing recommendations within areal-world sample. Our study underscores the need for additional research on chatbot functionality in patient therapy decision-making, further fostering the advance-ment of AI for optimal performance.
PB  - John Wiley and Sons Inc
T2  - British Journal of Clinical Pharmacology
T1  - Clinical decision-making in benzodiazepine deprescribing by healthcare providers vs. AI-assisted approach
VL  - 90
IS  - 3
SP  - 662
EP  - 674
DO  - 10.1111/bcp.15963
ER  - 
@article{
author = "Bužančić, Iva and Belec, Dora and Držaić, Margita and Kummer, Ingrid and Brkić, Jovana and Fialová, Daniela and Ortner Hadžiabdić, Maja",
year = "2024",
abstract = "Aims: The aim of this study was to compare the clinical decision-making for benzodiazepine deprescribing between a healthcare provider (HCP) and an artificial intelligence (AI) chatbot GPT4 (ChatGPT-4). Methods: We analysed real-world data from a Croatian cohort of community-dwelling benzodiazepine patients (n = 154) within the EuroAgeism H2020 ESR 7 project. HCPs evaluated the data using pre-established deprescribing criteria to assess benzodiazepine discontinuation potential. The research team devised and tested AI prompts to ensure consistency with HCP judgements. An independent researcher employed ChatGPT-4 with predetermined prompts to simulate clinical decisions for each patient case. Data derived from human-HCP and ChatGPT-4 decisions were compared for agreement rates and Cohen's kappa. 
Results : Both HPC and ChatGPT identified patients for benzodiazepine deprescribing (96.1% and 89.6%, respectively), showing an agreement rate of 95% (κ=.200,P=.012). Agreement on four deprescribing criteria ranged from 74.7% to 91.3%(lack of indicationκ=.352,P< .001; prolonged useκ=.088,P=.280; safety concernsκ=.123,P=.006; incorrect dosageκ=.264,P=.001). Important limitationsof GPT-4 responses were identified, including 22.1% ambiguous outputs, genericanswers and inaccuracies, posing inappropriate decision-making risks.Conclusions : While AI-HCP agreement is substantial, sole AI reliance poses a risk forunsuitable clinical decision-making. This study's findings reveal both strengths andareas for enhancement of ChatGPT-4 in the deprescribing recommendations within areal-world sample. Our study underscores the need for additional research on chatbot functionality in patient therapy decision-making, further fostering the advance-ment of AI for optimal performance.",
publisher = "John Wiley and Sons Inc",
journal = "British Journal of Clinical Pharmacology",
title = "Clinical decision-making in benzodiazepine deprescribing by healthcare providers vs. AI-assisted approach",
volume = "90",
number = "3",
pages = "662-674",
doi = "10.1111/bcp.15963"
}
Bužančić, I., Belec, D., Držaić, M., Kummer, I., Brkić, J., Fialová, D.,& Ortner Hadžiabdić, M.. (2024). Clinical decision-making in benzodiazepine deprescribing by healthcare providers vs. AI-assisted approach. in British Journal of Clinical Pharmacology
John Wiley and Sons Inc., 90(3), 662-674.
https://doi.org/10.1111/bcp.15963
Bužančić I, Belec D, Držaić M, Kummer I, Brkić J, Fialová D, Ortner Hadžiabdić M. Clinical decision-making in benzodiazepine deprescribing by healthcare providers vs. AI-assisted approach. in British Journal of Clinical Pharmacology. 2024;90(3):662-674.
doi:10.1111/bcp.15963 .
Bužančić, Iva, Belec, Dora, Držaić, Margita, Kummer, Ingrid, Brkić, Jovana, Fialová, Daniela, Ortner Hadžiabdić, Maja, "Clinical decision-making in benzodiazepine deprescribing by healthcare providers vs. AI-assisted approach" in British Journal of Clinical Pharmacology, 90, no. 3 (2024):662-674,
https://doi.org/10.1111/bcp.15963 . .
1

Deprescribing potential of commonly used medications among community-dwelling older adults: insights from a pharmacist’s geriatric assessment

Bužančić, Iva; Držaić, Margita; Kummer, Ingrid; Ortner Hadžiabdić, Maja; Brkić, Jovana; Fialová, Daniela

(Nature Research, 2024)

TY  - JOUR
AU  - Bužančić, Iva
AU  - Držaić, Margita
AU  - Kummer, Ingrid
AU  - Ortner Hadžiabdić, Maja
AU  - Brkić, Jovana
AU  - Fialová, Daniela
PY  - 2024
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5571
AB  - Pharmacist’s geriatric assessment can provide valuable insights into potential deprescribing targets, while including important information on various health-related domains. Data collected from a geriatric assessment questionnaire, for 388 patients, from the Croatian cohort of the EuroAgeism H2020 ESR 7 international project, along with guideline-based deprescribing criteria, were used to analyse potentially inappropriate prescribing of four medication groups (benzodiazepines (BZN), proton pump inhibitors (PPI), opioids, and non-steroidal anti-inflammatory drugs (NSAID)), and to assess the deprescribing potential. Binary logistic regression was used to explore the effects of age, gender, number of medicines and diagnoses, self-reported health, frailty score, and healthcare utilization on the likelihood of needing deprescribing. More than half of participants (n = 216, 55.2%) are candidates for deprescribing, with 31.1% of PPI, 74.8% of NSAID, 75% of opioid, and 96.1% of BZN users meeting at least one criterion. Most common criteria for deprescribing were inappropriately long use and safety concerns. Women (aOR = 2.58; p < 0.001), those reporting poor self-reported health (aOR = 5.14; p < 0.001), and those exposed to polypharmacy (aOR = 1.29; p < 0.001) had higher odds of needing to have medicines deprescribed. The high rate of deprescribing potential warrants prompt action to increase patient safety and decrease polypharmacy. Pharmacist’s geriatric assessment and deprescribing-focused medication review could be used to lead a personalised approach.
PB  - Nature Research
T2  - Scientific Reports
T1  - Deprescribing potential of commonly used medications among community-dwelling older adults: insights from a pharmacist’s geriatric assessment
VL  - 14
IS  - 1
SP  - 6235
DO  - 10.1038/s41598-024-56780-1
ER  - 
@article{
author = "Bužančić, Iva and Držaić, Margita and Kummer, Ingrid and Ortner Hadžiabdić, Maja and Brkić, Jovana and Fialová, Daniela",
year = "2024",
abstract = "Pharmacist’s geriatric assessment can provide valuable insights into potential deprescribing targets, while including important information on various health-related domains. Data collected from a geriatric assessment questionnaire, for 388 patients, from the Croatian cohort of the EuroAgeism H2020 ESR 7 international project, along with guideline-based deprescribing criteria, were used to analyse potentially inappropriate prescribing of four medication groups (benzodiazepines (BZN), proton pump inhibitors (PPI), opioids, and non-steroidal anti-inflammatory drugs (NSAID)), and to assess the deprescribing potential. Binary logistic regression was used to explore the effects of age, gender, number of medicines and diagnoses, self-reported health, frailty score, and healthcare utilization on the likelihood of needing deprescribing. More than half of participants (n = 216, 55.2%) are candidates for deprescribing, with 31.1% of PPI, 74.8% of NSAID, 75% of opioid, and 96.1% of BZN users meeting at least one criterion. Most common criteria for deprescribing were inappropriately long use and safety concerns. Women (aOR = 2.58; p < 0.001), those reporting poor self-reported health (aOR = 5.14; p < 0.001), and those exposed to polypharmacy (aOR = 1.29; p < 0.001) had higher odds of needing to have medicines deprescribed. The high rate of deprescribing potential warrants prompt action to increase patient safety and decrease polypharmacy. Pharmacist’s geriatric assessment and deprescribing-focused medication review could be used to lead a personalised approach.",
publisher = "Nature Research",
journal = "Scientific Reports",
title = "Deprescribing potential of commonly used medications among community-dwelling older adults: insights from a pharmacist’s geriatric assessment",
volume = "14",
number = "1",
pages = "6235",
doi = "10.1038/s41598-024-56780-1"
}
Bužančić, I., Držaić, M., Kummer, I., Ortner Hadžiabdić, M., Brkić, J.,& Fialová, D.. (2024). Deprescribing potential of commonly used medications among community-dwelling older adults: insights from a pharmacist’s geriatric assessment. in Scientific Reports
Nature Research., 14(1), 6235.
https://doi.org/10.1038/s41598-024-56780-1
Bužančić I, Držaić M, Kummer I, Ortner Hadžiabdić M, Brkić J, Fialová D. Deprescribing potential of commonly used medications among community-dwelling older adults: insights from a pharmacist’s geriatric assessment. in Scientific Reports. 2024;14(1):6235.
doi:10.1038/s41598-024-56780-1 .
Bužančić, Iva, Držaić, Margita, Kummer, Ingrid, Ortner Hadžiabdić, Maja, Brkić, Jovana, Fialová, Daniela, "Deprescribing potential of commonly used medications among community-dwelling older adults: insights from a pharmacist’s geriatric assessment" in Scientific Reports, 14, no. 1 (2024):6235,
https://doi.org/10.1038/s41598-024-56780-1 . .

Prevalence, country-specific prescribing patterns and determinants of benzodiazepine use in community-residing older adults in 7 European countries

Lukačišinová, Anna; Reissigová, Jindra; Ortner-Hadžiabdić, Maja; Brkić, Jovana; Okuyan, Betul; Volmer, Daisy; Tadić, Ivana; Modamio, Pilar; Mariño, Eduardo; Tachkov, Konstantine; Liperotti, Rosa; Onder, Graziano; Finne-Soveri, Harriet; van Hout, Hein; Howard, Elizabeth P.; Fialová, Daniela

(BioMed Central Ltd, 2024)

TY  - JOUR
AU  - Lukačišinová, Anna
AU  - Reissigová, Jindra
AU  - Ortner-Hadžiabdić, Maja
AU  - Brkić, Jovana
AU  - Okuyan, Betul
AU  - Volmer, Daisy
AU  - Tadić, Ivana
AU  - Modamio, Pilar
AU  - Mariño, Eduardo
AU  - Tachkov, Konstantine
AU  - Liperotti, Rosa
AU  - Onder, Graziano
AU  - Finne-Soveri, Harriet
AU  - van Hout, Hein
AU  - Howard, Elizabeth P.
AU  - Fialová, Daniela
PY  - 2024
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5563
AB  - Background: The use of benzodiazepines (BZDs) in older population is often accompanied by drug-related complications. Inappropriate BZD use significantly alters older adults’ clinical and functional status. This study compares the prevalence, prescribing patterns and factors associated with BZD use in community-dwelling older patients in 7 European countries. Methods: International, cross-sectional study was conducted in community-dwelling older adults (65 +) in the Czech Republic, Serbia, Estonia, Bulgaria, Croatia, Turkey, and Spain between Feb2019 and Mar2020. Structured and standardized questionnaire based on interRAI assessment scales was applied. Logistic regression was used to evaluate factors associated with BZD use. Results: Out of 2,865 older patients (mean age 73.2 years ± 6.8, 61.2% women) 14.9% were BZD users. The highest prevalence of BZD use was identified in Croatia (35.5%), Spain (33.5%) and Serbia (31.3%). The most frequently prescribed BZDs were diazepam (27.9% of 426 BZD users), alprazolam (23.7%), bromazepam (22.8%) and lorazepam (16.7%). Independent factors associated with BZD use were female gender (OR 1.58, 95%CI 1.19–2.10), hyperpolypharmacy (OR 1.97, 95%CI 1.22–3.16), anxiety (OR 4.26, 95%CI 2.86–6.38), sleeping problems (OR 4.47, 95%CI 3.38–5.92), depression (OR 1.95, 95%CI 1.29–2.95), repetitive anxious complaints (OR 1.77, 95%CI 1.29–2.42), problems with syncope (OR 1.78, 95%CI 1.03–3.06), and loss of appetite (OR 0.60, 95%CI 0.38–0.94). In comparison to Croatia, residing in other countries was associated with lower odds of BZD use (ORs varied from 0.49 (95%CI 0.32–0.75) in Spain to 0.01 (95%CI 0.00–0.03) in Turkey), excluding Serbia (OR 1.11, 95%CI 0.79–1.56). Conclusions: Despite well-known negative effects, BZDs are still frequently prescribed in older outpatient population in European countries. Principles of safer geriatric prescribing and effective deprescribing strategies should be individually applied in older BZD users.
PB  - BioMed Central Ltd
T2  - BMC Geriatrics
T1  - Prevalence, country-specific prescribing patterns and determinants of benzodiazepine use in community-residing older adults in 7 European countries
VL  - 24
IS  - 1
DO  - 10.1186/s12877-024-04742-7
ER  - 
@article{
author = "Lukačišinová, Anna and Reissigová, Jindra and Ortner-Hadžiabdić, Maja and Brkić, Jovana and Okuyan, Betul and Volmer, Daisy and Tadić, Ivana and Modamio, Pilar and Mariño, Eduardo and Tachkov, Konstantine and Liperotti, Rosa and Onder, Graziano and Finne-Soveri, Harriet and van Hout, Hein and Howard, Elizabeth P. and Fialová, Daniela",
year = "2024",
abstract = "Background: The use of benzodiazepines (BZDs) in older population is often accompanied by drug-related complications. Inappropriate BZD use significantly alters older adults’ clinical and functional status. This study compares the prevalence, prescribing patterns and factors associated with BZD use in community-dwelling older patients in 7 European countries. Methods: International, cross-sectional study was conducted in community-dwelling older adults (65 +) in the Czech Republic, Serbia, Estonia, Bulgaria, Croatia, Turkey, and Spain between Feb2019 and Mar2020. Structured and standardized questionnaire based on interRAI assessment scales was applied. Logistic regression was used to evaluate factors associated with BZD use. Results: Out of 2,865 older patients (mean age 73.2 years ± 6.8, 61.2% women) 14.9% were BZD users. The highest prevalence of BZD use was identified in Croatia (35.5%), Spain (33.5%) and Serbia (31.3%). The most frequently prescribed BZDs were diazepam (27.9% of 426 BZD users), alprazolam (23.7%), bromazepam (22.8%) and lorazepam (16.7%). Independent factors associated with BZD use were female gender (OR 1.58, 95%CI 1.19–2.10), hyperpolypharmacy (OR 1.97, 95%CI 1.22–3.16), anxiety (OR 4.26, 95%CI 2.86–6.38), sleeping problems (OR 4.47, 95%CI 3.38–5.92), depression (OR 1.95, 95%CI 1.29–2.95), repetitive anxious complaints (OR 1.77, 95%CI 1.29–2.42), problems with syncope (OR 1.78, 95%CI 1.03–3.06), and loss of appetite (OR 0.60, 95%CI 0.38–0.94). In comparison to Croatia, residing in other countries was associated with lower odds of BZD use (ORs varied from 0.49 (95%CI 0.32–0.75) in Spain to 0.01 (95%CI 0.00–0.03) in Turkey), excluding Serbia (OR 1.11, 95%CI 0.79–1.56). Conclusions: Despite well-known negative effects, BZDs are still frequently prescribed in older outpatient population in European countries. Principles of safer geriatric prescribing and effective deprescribing strategies should be individually applied in older BZD users.",
publisher = "BioMed Central Ltd",
journal = "BMC Geriatrics",
title = "Prevalence, country-specific prescribing patterns and determinants of benzodiazepine use in community-residing older adults in 7 European countries",
volume = "24",
number = "1",
doi = "10.1186/s12877-024-04742-7"
}
Lukačišinová, A., Reissigová, J., Ortner-Hadžiabdić, M., Brkić, J., Okuyan, B., Volmer, D., Tadić, I., Modamio, P., Mariño, E., Tachkov, K., Liperotti, R., Onder, G., Finne-Soveri, H., van Hout, H., Howard, E. P.,& Fialová, D.. (2024). Prevalence, country-specific prescribing patterns and determinants of benzodiazepine use in community-residing older adults in 7 European countries. in BMC Geriatrics
BioMed Central Ltd., 24(1).
https://doi.org/10.1186/s12877-024-04742-7
Lukačišinová A, Reissigová J, Ortner-Hadžiabdić M, Brkić J, Okuyan B, Volmer D, Tadić I, Modamio P, Mariño E, Tachkov K, Liperotti R, Onder G, Finne-Soveri H, van Hout H, Howard EP, Fialová D. Prevalence, country-specific prescribing patterns and determinants of benzodiazepine use in community-residing older adults in 7 European countries. in BMC Geriatrics. 2024;24(1).
doi:10.1186/s12877-024-04742-7 .
Lukačišinová, Anna, Reissigová, Jindra, Ortner-Hadžiabdić, Maja, Brkić, Jovana, Okuyan, Betul, Volmer, Daisy, Tadić, Ivana, Modamio, Pilar, Mariño, Eduardo, Tachkov, Konstantine, Liperotti, Rosa, Onder, Graziano, Finne-Soveri, Harriet, van Hout, Hein, Howard, Elizabeth P., Fialová, Daniela, "Prevalence, country-specific prescribing patterns and determinants of benzodiazepine use in community-residing older adults in 7 European countries" in BMC Geriatrics, 24, no. 1 (2024),
https://doi.org/10.1186/s12877-024-04742-7 . .

Author Correction: Prevalence of potentially inappropriate prescribing in older adults in Central and Eastern Europe: a systematic review and synthesis without meta‑analysis

Brkić, Jovana; Fialova, Daniela; Okuyan, Betul; Kummer, Ingrid; Šesto, Sofija; Capiau, Andreas; Ortner Hadžiabdić, Maja; Tachkov, Konstantin; Bobrova, Veera

(Nature Research, 2022)

TY  - JOUR
AU  - Brkić, Jovana
AU  - Fialova, Daniela
AU  - Okuyan, Betul
AU  - Kummer, Ingrid
AU  - Šesto, Sofija
AU  - Capiau, Andreas
AU  - Ortner Hadžiabdić, Maja
AU  - Tachkov, Konstantin
AU  - Bobrova, Veera
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4345
PB  - Nature Research
T2  - Scientific Reports
T1  - Author Correction: Prevalence of potentially inappropriate prescribing in older adults in Central and Eastern Europe: a systematic review and synthesis without meta‑analysis
VL  - 12
IS  - 1
DO  - 10.1038/s41598-022-25155-9
ER  - 
@article{
author = "Brkić, Jovana and Fialova, Daniela and Okuyan, Betul and Kummer, Ingrid and Šesto, Sofija and Capiau, Andreas and Ortner Hadžiabdić, Maja and Tachkov, Konstantin and Bobrova, Veera",
year = "2022",
publisher = "Nature Research",
journal = "Scientific Reports",
title = "Author Correction: Prevalence of potentially inappropriate prescribing in older adults in Central and Eastern Europe: a systematic review and synthesis without meta‑analysis",
volume = "12",
number = "1",
doi = "10.1038/s41598-022-25155-9"
}
Brkić, J., Fialova, D., Okuyan, B., Kummer, I., Šesto, S., Capiau, A., Ortner Hadžiabdić, M., Tachkov, K.,& Bobrova, V.. (2022). Author Correction: Prevalence of potentially inappropriate prescribing in older adults in Central and Eastern Europe: a systematic review and synthesis without meta‑analysis. in Scientific Reports
Nature Research., 12(1).
https://doi.org/10.1038/s41598-022-25155-9
Brkić J, Fialova D, Okuyan B, Kummer I, Šesto S, Capiau A, Ortner Hadžiabdić M, Tachkov K, Bobrova V. Author Correction: Prevalence of potentially inappropriate prescribing in older adults in Central and Eastern Europe: a systematic review and synthesis without meta‑analysis. in Scientific Reports. 2022;12(1).
doi:10.1038/s41598-022-25155-9 .
Brkić, Jovana, Fialova, Daniela, Okuyan, Betul, Kummer, Ingrid, Šesto, Sofija, Capiau, Andreas, Ortner Hadžiabdić, Maja, Tachkov, Konstantin, Bobrova, Veera, "Author Correction: Prevalence of potentially inappropriate prescribing in older adults in Central and Eastern Europe: a systematic review and synthesis without meta‑analysis" in Scientific Reports, 12, no. 1 (2022),
https://doi.org/10.1038/s41598-022-25155-9 . .

Pharmacists' role, work practices, and safety measures against COVID-19: A comparative study

Novak, Helena; Tadić, Ivana; Falamić, Slaven; Ortner Hadžiabdić, Maja

(Elsevier B.V., 2021)

TY  - JOUR
AU  - Novak, Helena
AU  - Tadić, Ivana
AU  - Falamić, Slaven
AU  - Ortner Hadžiabdić, Maja
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4208
AB  - Background: The coronavirus disease 2019 (COVID-19) pandemic poses a great challenge to health systems and their most accessible assets-community pharmacies. Pharmacists faced many challenges such as incorporating safety measures, changes in working schedule and workload, and meeting specific patients' needs.

Objectives: This study aimed to explore and compare the community pharmacists' roles, practices, implemented safety measures, and psychological toll in Croatia and Serbia during the COVID-19 pandemic.

Methods: A cross-sectional study employing an online survey was conducted in 2 countries over a period of 6 weeks during 2020. The survey consisted of 65 items that explored sociodemographic characteristics of participants and their workplaces, including safety measures, pharmaceutical care, and their psychology while working during the COVID-19 pandemic.

Results: In total, 574 pharmacists participated in the study, of which, 90% were female, with a mean age of 38 years (interquartile range 30.5-47). The study identified new pharmacists' roles that evolved during the COVID-19 pandemic: manufacturing hand sanitizers in community pharmacies, online patient counseling, and home delivery of medicines. Croatian and Serbian pharmacists exhibited disparities in their incorporated safety measures (higher for Croatia; P ≤ 0.001) and satisfaction with work organization and counseling activities (higher for Serbia; P < 0.001). Serbian participants were less satisfied with the public perception of their role during the pandemic, and overall satisfaction was low, with a negative impact on mood and productivity.

Conclusions: The study revealed the implications for community pharmacists during the pandemic in both countries. The extent of systematic and logistical support provided to them during the pandemic could be an explanation for the highlighted differences. It is imperative to develop a more effective strategy to counter potential health crises to ensure a better response from primary care pharmacists in the future.
PB  - Elsevier B.V.
T2  - Journal of the American Pharmacists Association
T1  - Pharmacists' role, work practices, and safety measures against COVID-19: A comparative study
VL  - 61
IS  - 4
SP  - 398
EP  - 407
DO  - 10.1016/j.japh.2021.03.006.
ER  - 
@article{
author = "Novak, Helena and Tadić, Ivana and Falamić, Slaven and Ortner Hadžiabdić, Maja",
year = "2021",
abstract = "Background: The coronavirus disease 2019 (COVID-19) pandemic poses a great challenge to health systems and their most accessible assets-community pharmacies. Pharmacists faced many challenges such as incorporating safety measures, changes in working schedule and workload, and meeting specific patients' needs.

Objectives: This study aimed to explore and compare the community pharmacists' roles, practices, implemented safety measures, and psychological toll in Croatia and Serbia during the COVID-19 pandemic.

Methods: A cross-sectional study employing an online survey was conducted in 2 countries over a period of 6 weeks during 2020. The survey consisted of 65 items that explored sociodemographic characteristics of participants and their workplaces, including safety measures, pharmaceutical care, and their psychology while working during the COVID-19 pandemic.

Results: In total, 574 pharmacists participated in the study, of which, 90% were female, with a mean age of 38 years (interquartile range 30.5-47). The study identified new pharmacists' roles that evolved during the COVID-19 pandemic: manufacturing hand sanitizers in community pharmacies, online patient counseling, and home delivery of medicines. Croatian and Serbian pharmacists exhibited disparities in their incorporated safety measures (higher for Croatia; P ≤ 0.001) and satisfaction with work organization and counseling activities (higher for Serbia; P < 0.001). Serbian participants were less satisfied with the public perception of their role during the pandemic, and overall satisfaction was low, with a negative impact on mood and productivity.

Conclusions: The study revealed the implications for community pharmacists during the pandemic in both countries. The extent of systematic and logistical support provided to them during the pandemic could be an explanation for the highlighted differences. It is imperative to develop a more effective strategy to counter potential health crises to ensure a better response from primary care pharmacists in the future.",
publisher = "Elsevier B.V.",
journal = "Journal of the American Pharmacists Association",
title = "Pharmacists' role, work practices, and safety measures against COVID-19: A comparative study",
volume = "61",
number = "4",
pages = "398-407",
doi = "10.1016/j.japh.2021.03.006."
}
Novak, H., Tadić, I., Falamić, S.,& Ortner Hadžiabdić, M.. (2021). Pharmacists' role, work practices, and safety measures against COVID-19: A comparative study. in Journal of the American Pharmacists Association
Elsevier B.V.., 61(4), 398-407.
https://doi.org/10.1016/j.japh.2021.03.006.
Novak H, Tadić I, Falamić S, Ortner Hadžiabdić M. Pharmacists' role, work practices, and safety measures against COVID-19: A comparative study. in Journal of the American Pharmacists Association. 2021;61(4):398-407.
doi:10.1016/j.japh.2021.03.006. .
Novak, Helena, Tadić, Ivana, Falamić, Slaven, Ortner Hadžiabdić, Maja, "Pharmacists' role, work practices, and safety measures against COVID-19: A comparative study" in Journal of the American Pharmacists Association, 61, no. 4 (2021):398-407,
https://doi.org/10.1016/j.japh.2021.03.006. . .
1
11